Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS known ✓ | P04818 | 8/20 | 1.00 |
| ▸ | GART known ✓ | P22102 | 8/20 | 0.75 |
| ▸ | DHFR known ✓ | P00374 | 4/20 | 0.75 |
| ▸ | FOLR1 | P15328 | 7/20 | 0.75 |
| ▸ | SLC46A1 | Q96NT5 | 7/20 | 0.75 |
| ▸ | SLC19A1 | P41440 | 6/20 | 0.75 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.75 |
| ▸ | ATIC | P31939 | 2/20 | 0.75 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.75 |
| ▸ | FRK | P42685 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL6076020 | 1.00 | TYMS (1.00) | TYMSGARTFOLR1SLC46A1SLC19A1 | |
| Pemetrexed SCHEMBL6075234 | 0.99 | TYMS (0.98) | TYMSGARTFOLR1SLC46A1SLC19A1 | |
| Pemetrexed SCHEMBL6075227 | 0.99 | TYMS (0.98) | TYMSGARTFOLR1SLC46A1SLC19A1 | |
| SCHEMBL7143669 | 0.94 | TYMS (0.89) | TYMSGARTFOLR1SLC46A1SLC19A1 | |
| Pemetrexed SCHEMBL18348 | 0.88 | TYMS (0.78) | TYMSGARTFOLR1SLC46A1SLC19A1 | |
| Pemetrexed SCHEMBL1651788 | 0.88 | TYMS (0.78) | TYMSGARTFOLR1SLC46A1SLC19A1 | |
| Pemetrexed SCHEMBL5333210 | 0.88 | TYMS (0.78) | TYMSGARTFOLR1SLC46A1SLC19A1 | |
| Pemetrexed SCHEMBL1934530 | 0.87 | TYMS (0.77) | TYMSGARTFOLR1SLC46A1SLC19A1 | |
| Pemetrexed SCHEMBL21599244 | 0.87 | TYMS (0.77) | TYMSGARTFOLR1SLC46A1SLC19A1 | |
| Pemetrexed SCHEMBL135815 | 0.87 | TYMS (0.77) | TYMSGARTFOLR1SLC46A1SLC19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118619955-A | Preparation method and application of pemetrexed key intermediate | 江苏海洋大学 | 2024-09-10 | — | — | CN | claimed |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2022-03-24 | — | — | US | claimed |
| US-7138521-B2 | Crystalline of N-[4-[2-(2-Amino-4,7-dihydro-4oxo-3H-pyrrolo[2,3-D]pyrimidin-5-YL)ethyl]benzoyl]-L-glutamic acid and process therefor | ELI LILLY AND COMPANY (US) | 2006-11-21 | — | — | US | claimed |
| US-20030216416-A1 | Novel crystalline of n-[4-[2-(2-amino-4,7-dihydro-4oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor | ELI LILLY AND COMPANY | 2003-11-20 | — | — | US | claimed |
| JP-2003530321-A | — | — | 2003-10-14 | — | — | JP | claimed |
| EP-1259513-B1 | A NOVEL CRYSTALLINE FORM OF N- 4- 2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO 2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR | LILLY CO ELI (US) | 2003-09-10 | — | — | EP | claimed |
| EP-1259513-A2 | A NOVEL CRYSTALLINE FORM OF N- 4- 2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO 2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR | ELI LILLY AND COMPANY (US) | 2002-11-27 | — | — | EP | claimed |
| EP-1212325-A2 | A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR | ELI LILLY AND COMPANY (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001062760-A2 | A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR | ELI LILLY AND COMPANY (US) | 2001-08-30 | — | — | WO | claimed |
| WO-2001014379-A2 | A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR | ELI LILLY AND COMPANY (US) | 2001-03-01 | — | — | WO | claimed |
| CN-116723837-B | Solid forms of CDK2 inhibitors | PFIZER INC. (US) | 2026-05-26 | — | — | CN | disclosed |
| CN-121287594-A | Sustained release implant containing pemetrexed and application thereof | 江苏泰中药业有限公司 | 2026-01-09 | — | — | CN | disclosed |
| US-20250228788-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-17 | — | — | US | disclosed |
| CN-114085238-B | Preparation method of high-purity pemetrexed disodium dimer impurity | 重庆凯林制药有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250170067-A1 | Carrier-Binding Agent Compositions and Methods of Making and Using the Same | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-05-29 | — | — | US | disclosed |
| EP-1212325-A2 | A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR | ELI LILLY AND COMPANY (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014379-A3 | A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR | LILLY CO ELI (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001062760-A2 | A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR | ELI LILLY AND COMPANY (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001014379-A2 | A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR | ELI LILLY AND COMPANY (US) | 2001-03-01 | — | — | WO | disclosed |
| WO-2001014379-A2 | A NOVEL CRYSTALLINE FORM OF DISODIUM N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-D]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID SALT AND PROCESSES THEREFOR | ELI LILLY AND COMPANY (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | TYMS 2998/4885GART 2409/4885DHFR 2391/4885 |
| US-20030216416-A1 | Novel crystalline of n-[4-[2-(2-amino-4,7-dihydro-4oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor | SLC7A11, SLC7A1, DHFR | TYMS 119/4885GART 71/4885DHFR 3/4885 |
| US-20250228788-A1 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | POLRMT, FABP1, SNRPE | TYMS 2122/4885GART 3414/4885DHFR 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.